ClinicalTrials.gg
CompletedNCT06213844Updated Nov 21, 2025

A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics

A Phase 1 interventional study of IBI3002 and Placebo in Healthy Participants and Asthma, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 128 studies in Asthma with a site in Australia — 7 open to participants now, 12 under way, 5 of them phase 3. Asthma · Australia.

Enrollment
88th of 120
52 · median 244
Started
2024
with 4 others
Phase 1
29 of 128
1 open now
Registered
114th of 128
by date

Among the 128 studies in Asthma with a site in Australia, this one is the 88th largest by enrollment of the 120 interventional ones that give a count, is one of 5 that started in 2024, is one of 29 in phase 1, and was the 114th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 128 studies in Asthma with a site in Australia are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Asthma with a site in Australia, or all of them as a file.
02

Study summary

This is a single-center, randomized, double-blind, placebo-controlled, phase 1, single-ascending-dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of IBI3002 in healthy participants and mild to moderate asthmatics. Subjects will be randomly assigned to different dosages of IBI3002 and matched placebo groups. The entire trial cycle includes a 4-week screening period, 1-day treatment period and 5-week follow-up period.

03

Conditions studied

  • Healthy Participants
  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must sign an Institutional Review Board (IRB) approved form before any study specific procedures.
  2. Participants must be between 18 and 55 years old, inclusive.
  3. Participants must have a (BMI) between 18 to 32 kg/m2, inclusive.
  4. Participants of and their partners should use highly effective methods of during the study and until 6 months after the study.
  5. Participants with asthma must have:

    • Documented physician diagnosis of asthma for at least 12 months prior to screening and confirmed by the investigator;
    • Elevated FeNO defined as ≥ 25ppb;
    • Documented and stable GINA 2023 recommended Step 1\~3 controller treatment (defined as ≤ 250μg fluticasone propionate dry powder formulation equivalent total daily dose of ICS, alone or in combination with LABA) for the last 3 months prior to screening;
    • Pre-BD ≥ 60% of prediction and Post-BD FEV1/forced vital capacity (FVC) > 70%.

Exclusion criteria

Exclusion Criteria:

  1. History of allergies to any components of IBI3002 or placebo.
  2. History of blood or needle sickness, or those who cannot tolerate venipuncture.
  3. Female participants who are pregnant or breastfeeding at screening or randomization.
  4. History of participating in a clinical trial within 1 month or 5 half-lives of the test drug (whichever is longer) prior to randomization, or those who are currently participating in a clinical trial.
  5. History of severe infection or significant injury within 6 months, or surgery within 3 months, or any infection requiring systemic medication within 1 month prior to screening or randomization.
  6. History of live or attenuated vaccination within 1 month prior to randomization, or those who plan to be vaccinated during the study.
  7. For asthmatics only: history of a life-threatening asthma attack that required mechanical ventilation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the last 5 years prior to randomization.
  8. For asthmatics only: history of asthma worsen or exacerbation resulting in emergency room (ER) visits or overnight hospitalizations, or an increase in asthma maintenance therapy, or use of systemic within the last 3 months prior to randomization.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Single dose of Placebo administered subcutaneously on Day 1

    Drug: Placebo

  • Experimental
    IBI3002

    Single dose of IBI3002 (Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, Dosage 6) administered subcutaneously on Day 1

    Drug: IBI3002

Interventions

  • Single dose of IBI3002 (Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, Dosage 6), administered subcutaneously on Day 1

    Also known as: ICS, alone or in combination with LABA

  • DrugPlacebo

    Single dose of Placebo, administered subcutaneously on Day 1

    Also known as: ICS, alone or in combination with LABA

06

What researchers measure

Primary outcomes

  1. Number of participants with AEs/SAEs

    Incidence of adverse events and severe adverse events

    Time frame: Baseline up to Day 36

Secondary outcomes

  1. PK parameter: Cmax

    Observed maximum plasma concentration

    Time frame: Baseline up to Day 36

  2. PK parameter: tmax

    Time to achieve Cmax

    Time frame: Baseline up to Day 36

  3. PK parameter: AUC

    Area under the plasma concentration-time curve

    Time frame: Baseline up to Day 36

  4. Immunogenicity profiles

    Frequency and titers of anti-drug antibody (ADA)

    Time frame: Baseline up to Day 36

  5. PD profile (only in asthmatics): TARC (CCL17)

    Change from baseline in peripheral blood TARC (CCL17) level

    Time frame: Baseline up to Day 36

  6. PD profile (only in asthmatics): IL-13

    Change from baseline in peripheral blood IL-13 level

    Time frame: Baseline up to Day 36

  7. PD profile (only in asthmatics): IgE

    Change from baseline in peripheral blood Immunoglobulin

    Time frame: Baseline up to Day 36

  8. PD profile (only in asthmatics): Eosinophil

    Change from baseline in peripheral blood eosinophil level

    Time frame: Baseline up to Day 36

  9. Clinical profile (only in asthmatics): FeNO

    Change from baseline in Fractional exhaled Nitric Oxide

    Time frame: Baseline up to Day 36

  10. Clinical profile (only in asthmatics): Spirometry

    Change from baseline in pre-bronchodilator forced expiratory volume in 1 second (Pre-BD FEV1)

    Time frame: Baseline up to Day 36

07

Study locations

1 site
  • Nucleus Network Pty Ltd
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jul 2025, 16 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 16 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2024
First posted
Jan 19, 2024
StartActual
Feb 26, 2024
Primary completionActual
Jul 22, 2025
CompletionActual
Sep 11, 2025
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06213844
Responsible party
Sponsor
First posted
Jan 19, 2024
Start date
Feb 26, 2024
Primary completion
Jul 22, 2025
Completion
Sep 11, 2025
Last update
Nov 21, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI3002

Start the discussion